C4 Therapeutics Inc. announced its third quarter 2025 financial results and recent business highlights. The company reported the completion of an equity offering that resulted in $125 million in gross proceeds, extending its financial runway to the end of 2028. There is also potential to earn up to an additional $225 million in proceeds. The company presented Phase 1 data of cemsidomide in combination with dexamethasone in multiple myeloma, showing a 40% overall response rate at the 75 µg dose level and a 53% overall response rate at the 100 µg dose level. One patient at the 100 µg dose level achieved a minimal residual disease (MRD) negative complete response. Cemsidomide was reported to be well-tolerated with a differentiated safety and tolerability profile. C4 Therapeutics also entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate cemsidomide in combination with elranatamab. The company plans to initiate a Phase 2 MOMENTUM trial in combination with dexamethasone in the first quarter of 2026 and a Phase 1b trial in combination with elranatamab in the second quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049850), on November 06, 2025, and is solely responsible for the information contained therein.
Comments